AstraZeneca Gilead Merger Intriguing But Unlikely
Bloomberg Rumor Causes A Stir
The possible creation of a pharma giant worth around $230bn of two firms who are leading the industry’s efforts to combat COVID-19 has caught the imagination but the likelihood of a match is limited.
